These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 19822620)

  • 1. Trial that pays patients to take antipsychotic drugs comes under attack.
    Eaton L
    BMJ; 2009 Oct; 339():b4202. PubMed ID: 19822620
    [No Abstract]   [Full Text] [Related]  

  • 2. Use of long-acting risperidone in psychiatric disorders: focus on efficacy, safety and cost-effectiveness.
    Keith S
    Expert Rev Neurother; 2009 Jan; 9(1):9-31. PubMed ID: 19102665
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Paliperidone palmitate - review of the efficacy, safety and cost of a new second-generation depot antipsychotic medication.
    Citrome L
    Int J Clin Pract; 2010 Jan; 64(2):216-39. PubMed ID: 19886879
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pharmacoeconomic review of the use of injectable long-acting risperidone].
    Bartkó G; Fehér L
    Neuropsychopharmacol Hung; 2005 Dec; 7(4):199-207. PubMed ID: 16496485
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Cost analysis of the strategies in the treatment of schizophrenics: the place of sustained release injectable atypical antipsychotics].
    Gasquet I; Bouhassira M; Launois R
    Encephale; 2005; 31(4 Pt 1):517-8. PubMed ID: 16389719
    [No Abstract]   [Full Text] [Related]  

  • 6. A Bayesian analysis of pharmacoeconomic data from a clinical trial on schizophrenia.
    Petit C; Maccario J
    Stat Med; 2003 Mar; 22(6):1025-39. PubMed ID: 12627416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Medication adherence and the use of long-acting antipsychotics in bipolar disorder.
    El-Mallakh RS
    J Psychiatr Pract; 2007 Mar; 13(2):79-85. PubMed ID: 17414683
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intramuscular haloperidol decanoate for neuroleptic maintenance therapy.
    arap Mengech HN; Wazome EG
    East Afr Med J; 1984 Jun; 61(6):435-8. PubMed ID: 6152736
    [No Abstract]   [Full Text] [Related]  

  • 9. The use of conventional antipsychotic medications for patients with schizophrenia in a medicaid population: therapeutic and cost outcomes over 2 years.
    McCombs JS; Luo M; Johnstone BM; Shi L
    Value Health; 2000; 3(3):222-31. PubMed ID: 16464186
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Now take a deep breath: inhaled loxapine for the treatment of acute agitation.
    Howland RH
    J Psychosoc Nurs Ment Health Serv; 2012 Jan; 50(1):16-8. PubMed ID: 22229963
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A review of brief medication-adherence instruments used in patients with schizophrenia and bipolar disorder.
    Pomykacz B; Mao M; Weiss RD; Teter CJ
    Harv Rev Psychiatry; 2007; 15(5):259-63. PubMed ID: 17924260
    [No Abstract]   [Full Text] [Related]  

  • 12. Methods of pharmacoeconomic evaluation of psychopharmacologic therapies for patients with schizophrenia.
    Revicki DA
    J Psychiatry Neurosci; 1997 Jul; 22(4):256-66. PubMed ID: 9262048
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Containing cost despite the cost.
    Farley JF
    Med Care; 2010 Jan; 48(1):1-3. PubMed ID: 19956078
    [No Abstract]   [Full Text] [Related]  

  • 14. [Expensive but nevertheless cost effect? Pharmacoeconomics of atypical neuroleptics].
    Laux G; Günther W
    Pharm Unserer Zeit; 2002; 31(6):572-6. PubMed ID: 12481515
    [No Abstract]   [Full Text] [Related]  

  • 15. Cost-effectiveness of schizophrenia pharmacotherapy.
    Soumerai SB; Law MR
    Am J Psychiatry; 2007 Apr; 164(4):678; author reply 678-9. PubMed ID: 17403984
    [No Abstract]   [Full Text] [Related]  

  • 16. Risperidone vs. placebo for schizophrenia.
    Kripke C
    Am Fam Physician; 2010 May; 81(9):1096. PubMed ID: 20433125
    [No Abstract]   [Full Text] [Related]  

  • 17. Outcomes, costs, and policy caution. A commentary on: the Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).
    Rosenheck RA
    Arch Gen Psychiatry; 2006 Oct; 63(10):1074-6. PubMed ID: 17015809
    [No Abstract]   [Full Text] [Related]  

  • 18. Depot antipsychotic preparations in schizophrenia: the state of the economic evidence.
    Knapp M; Ilson S; David A
    Int Clin Psychopharmacol; 2002 May; 17(3):135-40. PubMed ID: 11981355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paliperidone extended-release: a review of efficacy and tolerability in schizophrenia, schizoaffective disorder and bipolar mania.
    Canuso CM; Battisti WP
    Expert Opin Pharmacother; 2010 Oct; 11(15):2557-67. PubMed ID: 20854185
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Strategies for improving compliance in treatment of schizophrenia by using a long-acting formulation of an antipsychotic: clinical studies.
    Kane JM
    J Clin Psychiatry; 2003; 64 Suppl 16():34-40. PubMed ID: 14680417
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.